Merck takes Austria’s Keytruda price transparency battle to top court as journalists fight for information

Merck & Co. is challenging journalists' efforts to obtain pricing data for the cancer drug Keytruda in Austria's Constitutional Court. The dispute involves a freedom-of-information campaign by Austrian outlets profil and Der Standard, part of the Cancer Calculus investigation, which revealed Keytruda as the country's largest hospital medication expense.